Trial ID or NCT#

NCT00452413

Status

not recruiting iconNOT RECRUITING

Purpose

Phase I: A study to see what doses of Enzastaurin and Erlotinib are best tolerated by patients with solid tumor cancer. Phase II: A study to see how long patients with non-small cell lung cancer treated with Enzastaurin and Erlotinib live

Official Title

A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Heather Wakelee
Heather Wakelee
Medical oncologist, Thoracic specialist
Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

CONTACT

Melanie San Pedro-Salcedo
(650) 724-1388